Adalta Ltd
Research Adalta Ltd (1AD) on Bullrun: market cap AUD 9.64M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1AD
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 9.64M
- Financial periodFY2025
- Net income-AUD 4.50M
- Free cash flow-AUD 2.94M
Valuation Snapshot
latest market cap is AUD 9.64M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 4.50M | -AUD 2.94M | n/a | -0.01 | AUD 1.31M | AUD 1.77M | -AUD 598.24K |
| FY2024 | n/a | -AUD 5.38M | -AUD 5.32M | n/a | -0.01 | AUD 3.13M | AUD 2.70M | AUD 2.03M |
| FY2023 | n/a | -AUD 4.85M | -AUD 5.13M | n/a | -0.01 | AUD 4.79M | AUD 4.01M | AUD 1.91M |
| FY2022 | AUD 987.94K | -AUD 6.06M | -AUD 4.11M | 100.0% | -0.02 | AUD 8.74M | AUD 4.00M | AUD 5.38M |
| FY2021 | AUD 848.19K | n/a | n/a | 100.0% | n/a | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-18 | AUD 9.64M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Adalta Ltd
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Adalta Ltd's market cap?
Adalta Ltd's market capitalization is AUD 9.64M.
What does Adalta Ltd do?
AdAlta Limited, a clinical-stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. It has discovered WD-34 for the multiple malaria species, Babesia, and Toxoplasma in collaboration with La Trobe University.